Prevalence of Multiple Sclerosis in Dubai, United Arab Emirates

Inshasi, Jihad; Thakre, Mona

doi:10.3109/00207454.2011.565893

Cited by 70 publications

(66 citation statements)

References 30 publications

(26 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a recent paper in 2016 Schiess et al reported the prevalence of MS among Emiratis in Abu Dhabi (UAE) to be 57.09%, which is similar to another study from Dubai (UAE) in 2011 which determined the prevalence of 54.77% for the disease [26,27].…”

Section: Introductionsupporting

confidence: 57%

Hypovitaminosis D Status in Newly Diagnosed Cases of MS versus Control Group

Saeedan¹,

Ko²,

Chirakkara³

et al. 2017

J Mult Scler

View full text Add to dashboard Cite

Background: Hypovitaminosis D is amongst those strongly suggested risk factors for multiple sclerosis (MS). Although the association of vitamin D deficiency with MS has been established in several studies in recent years, there are not many studies to assess and compare the degree of Hypovitaminosis D status of newly diagnosed patients with multiple sclerosis versus control group worldwide, especially in UAE.

show abstract

Section: Introductionsupporting

confidence: 57%

Hypovitaminosis D Status in Newly Diagnosed Cases of MS versus Control Group

Saeedan¹,

Ko²,

Chirakkara³

et al. 2017

J Mult Scler

View full text Add to dashboard Cite

show abstract

“…We compared our results about gender distribution among MS patients attending KKUH with previous studies done globally and locally. [3,4,6,10,11] Among the MS population attending KKUH, we found that the vast majority of the patients were females. Similarly to almost all the studies that had been conducted.…”

Section: Discussionmentioning

confidence: 86%

“…A very close numbers were reported in a study conducted in Dubai, UAE where 72% of the native subjects included in the study presented with weakness. [10] In another study that was done in Jordan, with a sample size of 224 subjects, 30.8 % presented with weakness as the most frequent finding. This shows that weakness is more prevalent as a manifestation of MS in the region.…”

Section: Discussionmentioning

confidence: 96%

“…However, global studies did not report numbness as a manifestation either due to its minimal effect on the quality of daily life or its very early appearance in the course of the disease. [4,10] Visual impairment, on the other hand, was reported as the third most common manifestation affecting 48 % of the sample. Similarly, studies conducted in South Wales and Taiwan reported 40% and 38%, respectively.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The Pattern of First Multiple Sclerosis Presentation in Patients Attending King Khalid University Hospital (2000-2012)

2016

IJSR

View full text Add to dashboard Cite

Background: Multiple sclerosis is an autoimmune disease characterized by destruction of myelin in the central nervous system. In Saudi Arabia, there are no recent studies describing the pattern of the disease. Therefore, this study aims to describe the epidemiological pattern of multiple sclerosis and the most frequently encountered clinical manifestations of the disease. Methodology: All data were extracted by using questionnaires completed through reviewing all patients' medical record of all cases of MS that were admitted to KKUH between 2000 and 2012. Mean, standard deviation and Chi square were used for results presentation. Results: Among all patients, females were much more affected than males as they comprised 75.5% while males were 24.5%.The majority of patients were in their twenties and the mean age was 27.16 ±7.74 years. Most of the patients presented complaining of limb weakness (69.6%) followed by numbness (56.9%) then visual manifestations (47.5%). Conclusion: The majority of patients were females and the most frequently diagnosed age group was between 20 and 29 years old. Limb weakness was the most commonly experienced symptom among the patients followed by numbness then visual manifestations.

show abstract

“…Historically, the Kurtzke classification has designated many Middle Eastern countries as being low-risk zones for MS, but recent studies have shown that the crude incidence of MS in this region ranges from 31-85 per 100,000 individuals, and that the annual incidence is increasing [1][2][3][4]. Interferon-beta is generally regarded as the first-line treatment for MS, with natalizumab and fingolimod used as second-line agents in the case of treatment failure with interferon-beta [1].…”

Section: Introductionmentioning

confidence: 99%

Natalizumab treatment for multiple sclerosis: Middle East and North Africa regional recommendations for patient selection and monitoring

Alroughani¹,

Aref²,

Bohlega³

et al. 2014

Multiple Sclerosis and Related Disorders

View full text Add to dashboard Cite

Background: Natalizumab, a highly specific α4-integrin antagonist, , has recently been registered across the Middle East and North Africa region. It improves clinical and magnetic resonance imaging (MRI) outcomes and reduces the rate of relapse and disability progression in relapsing-remitting multiple sclerosis (MS). Natalizumab is recommended for patients who fail first-line disease-modifying therapy or who have very active disease. Progressive multifocal leukoencephalopathy is a rare, serious adverse event associated with natalizumab. We aim to develop regional recommendations for the selection and monitoring of MS patients to be treated with natalizumab in order to guide local neurological societies. Methods: After a review of available literature, a group of neurologists with expertise in the management of MS met to discuss the evidence and develop regional recommendations to guide appropriate use of natalizumab in the region. Results: Disease breakthrough is defined as either clinical (relapse or disability progression) or radiological activity (new T2 lesion or gadolinium-enhancing lesions on MRI), or a combination of both. Natalizumab is recommended as an escalation therapy in patients with breakthrough disease based on its established efficacy in Phase III studies. Several factors including prior immunosuppressant therapy, anti-John Cunningham virus (JCV) antibody status and patient choice will affect the selection of natalizumab. In highly active MS, natalizumab is considered as a first-line therapy for naive patients with disabling relapses in association with MRI activity. The anti-JCV antibody test is used to assess anti-JCV antibody status and identify the risk of PML. While seronegative patients should continue treatment with natalizumab, anti-JCV antibody testing every 6 months and annual MRI scans are recommended as part of patient monitoring. In seropositive patients, the expected benefits of natalizumab treatment have to be weighed against the risks of PML. Clinical vigilance and follow-up MRI scans remain the cornerstone of monitoring. After 2 years of natalizumab therapy, monitoring should include more frequent MRI scans (every 3-4 months) for seropositive patients, and the risk-benefit ratio should be reassessed and discussed with patients. Conclusions: Recommendations have been developed to guide neurologists in the Middle East and North Africa on patient selection for natalizumab treatment and monitoring.

show abstract

Prevalence of Multiple Sclerosis in Dubai, United Arab Emirates

Cited by 70 publications

References 30 publications

Hypovitaminosis D Status in Newly Diagnosed Cases of MS versus Control Group

Hypovitaminosis D Status in Newly Diagnosed Cases of MS versus Control Group

The Pattern of First Multiple Sclerosis Presentation in Patients Attending King Khalid University Hospital (2000-2012)

Natalizumab treatment for multiple sclerosis: Middle East and North Africa regional recommendations for patient selection and monitoring

Contact Info

Product

Resources

About